Publications
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome2020 | Publication without faculty affiliation
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial2019 | Publication without faculty affiliation
- Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes2019 | Publication without faculty affiliation
- Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial2019 | Publication without faculty affiliation
- Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial2019 | Publication without faculty affiliation
- Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery2019 | Publication without faculty affiliation
- Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial2019 | Publication without faculty affiliation
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome2018 | Publication without faculty affiliation
- Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)2010 | Second Faculty of Medicine
- Pregnancy-associated plasma protein A and proform eosinophilic major basic protein in the detection of different types of coronary artery disease2008 | Second Faculty of Medicine, First Faculty of Medicine, Faculty of Physical Education and Sport, Central Library of Charles University
Loading network view...